Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Food on EC-18 PK in Healthy Volunteers
NCT02700360Phase 1Completed
- Sponsor
- Enzychem Lifesciences
- Start
- Aug 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mosedipimod in chemotherapy-induced neutropenia (CIN) (6 arms), sponsored by Enzychem Lifesciences. Primary endpoints: Number and severity of Adverse Drug Reactions (ADRs), Vital Signs (change from baseline) and 3 more. Started Aug 2015; status: completed.
02
Drugs
mosedipimod
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT02700360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02700360.